Cargando…
Immune checkpoint blockades in gynecological cancers: A review of clinical trials
Advanced and recurrent gynecological cancers are associated with a poor prognosis and there is still a lack of effective treatments. Immune checkpoint blockade (ICB) therapy is an important element of cancer‐targeted therapy and immunotherapy. The programed cell death protein 1 (PD‐1) and cytotoxic...
Autores principales: | Peng, Hongling, He, Xiang, Wang, Qiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564814/ https://www.ncbi.nlm.nih.gov/pubmed/35751489 http://dx.doi.org/10.1111/aogs.14412 |
Ejemplares similares
-
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
por: Drakes, Maureen L., et al.
Publicado: (2020) -
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
por: Liu, Ying L., et al.
Publicado: (2018) -
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
por: Wang, Qiao, et al.
Publicado: (2020) -
Update on immune checkpoint inhibitors in gynecological cancers
por: Heong, Valerie, et al.
Publicado: (2017) -
Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)